^
    14d
    Beneficial Effects of Combining an Immune Checkpoint Inhibitor With Proton Radiation, OXi4503, or Hyperthermia in a Murine Solid Tumor Model. (PubMed, Anticancer Res)
    Overall, combining anti-CTLA-4 with either proton radiation or OXi4503, but not with hyperthermia, enhanced growth inhibition of C3H mammary carcinoma compared to that seen with each treatment alone, suggesting potential clinical relevance.
    Preclinical • Journal • Checkpoint inhibition • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    combretastatin A1 di-phosphate (OXi4503)
    almost6years
    Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents. (PubMed, Int J Mol Sci)
    Histological assessment of CD4/CD8 expression actually showed decreased levels up to 10 days after treatment with OXi4503 (50 mg/kg). Thus, the non-immunogenic C3H mammary carcinoma was unresponsive to checkpoint inhibitors, but became responsive in mice treated with VDAs, although the mechanism remains unclear.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    CD8 expression
    |
    combretastatin A1 di-phosphate (OXi4503)